Business Context and Reporting Period
This Form 8-K was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on February 26, 2019, with the report dated March 4, 2019. The filing discloses the entry into a material definitive agreement regarding the manufacturing and product development of the Company's cannabidiol (CBD) analogue formulation.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is related to the new agreement:
- Upfront Payment: $146,386 payable to Noramco, Inc.
- Additional Payments: To be made upon shipping of the active pharmaceutical ingredient (amount not specified).
Material Changes
The primary material change is the execution of a Master Development and Clinical Supply Agreement with Noramco, Inc. on February 26, 2019. This agreement establishes Noramco as the provider for manufacturing and product development services for Nemus's CBD analogue.
Outlook, Risks, and Contingencies
Agreement Terms and Termination Risks:
- Bankruptcy/Insolvency: Either party may terminate immediately if the other files for bankruptcy or becomes insolvent.
- Breach of Contract: Termination is permitted if a material breach is not cured within 45 days (30 days for payment breaches by the Company).
- Voluntary Termination: Either party may terminate with four (4) months' prior written notice.
- Liability upon Termination: The Company must pay for all services performed and non-cancelable commitments made up to the termination date.
Regulatory Disclosure: The Company issued a press release on March 4, 2019, regarding this agreement under Regulation FD.
Investor Verification Checklist
- Verify the full text of the Master Development and Clinical Supply Agreement (Exhibit 10.1) for omitted confidential terms.
- Confirm the total projected cost of the agreement, as only the upfront payment ($146,386) is disclosed.
- Review the Company's cash position to ensure it can meet the upfront payment and future shipping-based obligations.
- Monitor the status of the CBD analogue formulation development and any future press releases regarding clinical supply milestones.